Tilray Expands Annual Cannabis Cultivation Capacity Across EU-GMP-Certified Sites

Tilray Brands' decision to scale annual cultivation capacity from 210 to 275 metric tonnes across its Canadian and European sites signals a structural shift in how EU-GMP certification is being used to anchor international medical cannabis supply chains, a model with direct implications for any pharmaceutical manufacturer evaluating entry into regulated cannabis markets.

The capacity increase draws on two production nodes. Output at the Quebec facility has risen by 30 metric tonnes, with bulk cannabis now shipping directly to Tilray's sites in Portugal and Australia. That cross-border bulk transfer is only viable because the receiving sites hold EU-GMP certification, the quality standard that unlocks access to Germany, the United Kingdom, and other tightly regulated European markets. The Quebec facility itself is on track to achieve EU-GMP certification within 12 months, which would extend that supply flexibility upstream.

For QA directors and regulatory leads, the Portugal facility is the operational reference point. Described as one of Europe's largest medical cannabis production sites, it functions as the anchor of Tilray's European distribution network, feeding supply into markets where pharmacies and hospital formularies require GMP-compliant sourcing documentation. Germany's Aphria RX facility is reported as fully utilized, with the new ARX brand recording early commercial traction.

The vertical integration model Tilray is building, connecting scaled cultivation to pharmaceutical distribution channels and patient-access platforms such as HelloMD in Canada and Lyphe Clinic in the United Kingdom, reflects the compliance architecture that regulators in maturing cannabis markets increasingly expect. Plant heads entering these markets should note that certification at the cultivation site, not just the finished-product stage, is becoming a baseline requirement for cross-border supply agreements.

Tilray currently supplies medical cannabis to patients, physicians, hospitals, pharmacies, and government partners across 20 countries, a footprint that will be tested against the Quebec facility's EU-GMP certification timeline over the next four quarters.

Source: Tilray Brands via GlobeNewswire, 20 August 2026.